Harold Schaaff
@Soleus Capital Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$1.291BTotal holdings87
Assets growth rate13.9%Assets growth rate (2-Q avg)-0.97%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Soleus Capital Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 87 positions.
Assets under management
The assets under management (AUM) of Soleus Capital Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.291B in assets, with a quarterly growth rate of 13.9% and a 2-quarter average growth rate of -0.97%. The portfolio is managed by Harold Schaaff, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
IOVAIovance Biotherapeutics Inc
| 6.21% | $80.083M 8.529M shares@ $9.39 avg price | Increased 13% |
TERNTerns Pharmaceuticals Inc
| 4.02% | $51.904M 6.224M shares@ $8.35 avg price | Increased 25.79% |
KRYSKrystal Biotech Inc
| 3.06% | $39.497M 216,979 shares@ $182.03 avg price | Increased 72.21% |
CCCCC4 Therapeutics Inc
| 2.92% | $37.643M 6.604M shares@ $5.7 avg price | Increased 62.99% |
SNYSanofi
| 2.74% | $35.27M 612,000 shares@ $57.63 avg price | Increased 879.2% |
ORGOOrganogenesis Hldgs Inc
| 2.63% | $33.862M 11.84M shares@ $2.86 avg price | Increased 2.79% |
IDYAIdeaya Biosciences Inc
| 2.58% | $33.242M 1.049M shares@ $31.69 avg price | Increased 51.19% |
EPIXEssa Pharma Inc
| 2.02% | $25.986M 4.288M shares@ $6.06 avg price | Increased 1.85% |
JSPRJasper Therapeutics Inc
| 1.96% | $25.274M 1.344M shares@ $18.82 avg price | Increased 5.29% |
TXG10x Genomics Inc
| 1.67% | $21.474M 951,000 shares@ $22.58 avg price | Increased 32.27% |